Global Amyloidosis Treatment Market, By Type (Primary Amyloidosis, Secondary Amyloidosis, Dialysis-Related Amyloidosis and Others), Therapy Type (Chemotherapy and Targeted Therapy), Treatment Type (Medication and Surgery), Drugs (Transthyretin Transport Inhibitor, Immunomodulatory Drugs, Monoclonal Antibodies, Proteasome Inhibitors and Others), Route of Administration (Oral and Injectable), End Users (Hospitals, Homecare, Specialty Clinics and Others), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights of Amyloidosis Treatment Market
Data Bridge Market Research analyses that the amyloidosis treatment will exhibit a CAGR of around 7.17% for the forecast period of 2021-2028. Growing demand for targeted mode of therapies, surge in the research and development activities for the development of novel drugs and therapies, rising emergence of drugs used to treat risk associated with amyloidosis and increased expenditure for the development of healthcare infrastructure are the major factors attributable to the growth of amyloidosis treatment market.
Amyloidosis is an ultra-rare metabolic disorder that affects the functionality and shape of organs and tissues. This can give rise to life threatening diseases. Amyloidosis generally develops when amyloid protein is deposited in the tissues and organs.
Growing emergence of biologics is a major factor fostering the growth of the market. Rising expenditure on the development of healthcare infrastructure, ever-rising geriatric population and upsurge in the strategic collaboration rate among the market players are other factors also fostering the growth of the market. Increasing personal disposable income coupled with rising unmet needs for the treatment of this disease is other indirect determinant that will create lucrative market growth opportunities.
However, lack of awareness among people owing to the rarity of this disease will pose a major challenge to the market growth. Also, high costs associated with research and development proficiencies will further derail the market growth rate. High costs associated with the treatment will also hamper the market growth rate.
This amyloidosis treatment market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on amyloidosis treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Amyloidosis Treatment Market Scope and Market Size
The amyloidosis treatment market is segmented on the basis of type, therapy type, treatment type, drugs, route of administration and end users. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- On the basis of type, the amyloidosis treatment market is segmented into primary amyloidosis, secondary amyloidosis, dialysis-related amyloidosis and others.
- On the basis of therapy type, the amyloidosis treatment market is segmented into chemotherapy and targeted therapy.
- On the basis of treatment type, the amyloidosis treatment market is segmented into medication and surgery.
- On the basis of drugs, the amyloidosis treatment market is segmented into transthyretin transport inhibitor, immunomodulatory drugs, monoclonal antibodies, proteasome inhibitors and others. Transthyretin transport inhibitor segment is sub-segmented into patisiran, tafamidis and others. Immunomodulatory drugs segment is sub-segmented into lenalidomide and pomalidomide. Monoclonal antibodies segment is sub-segmented into daratumumab and elotuzumab. Proteasome inhibitors segment is sub-segmented into bortezomib, ixazomib and carfilzomib.
- On the basis of route of administration, the amyloidosis treatment market is segmented into oral and injectable.
- On the basis of end users, the amyloidosis treatment market is segmented into hospitals, home care, speciality clinics, and others.
Amyloidosis Treatment Market Country Level Analysis
The amyloidosis treatment market is analysed and market size insights and trends are provided by country, type, therapy type, treatment type, drugs, route of administration and end users as referenced above.
The countries covered in the amyloidosis treatment market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America dominates the amyloidosis treatment market owing to the rising expenditure for research and development proficiencies. Asia-Pacific is projected to score highest growth rate and exhibit the highest CAGR for the forecast period. This is because of the rising expenditure to develop healthcare infrastructure and growing prevalence of amyloidosis.
The country section of the amyloidosis treatment market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
The amyloidosis treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Amyloidosis Treatment Market Share Analysis
The amyloidosis treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to amyloidosis treatment market.
The major players covered in the amyloidosis treatment market report are Fortress Biotech, Inc., Takeda Pharmaceutical Company Ltd, Arcturus Therapeutics, Inc, Neurimmune, Pfizer Inc, Alnylam Pharmaceuticals, Inc, Proclara Biosciences, Prothena, Spectrum Pharmaceuticals, Inc, Ionis Pharmaceuticals, Inc, Johnson & Johnson Services, Inc, Celgene Corporation, Eidos Therapeutics, GlaxoSmithKline plc, Amgen Inc, Fresenius Kabi AG, Teva Pharmaceutical Industries Ltd, Mylan N.V., Novartis AG and Boehringer Ingelheim International GmbH among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-